Pain Relief After PrimaryTKA

NCT05751421 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Pain, Postoperative

Interventions

DRUG: Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution
DRUG: Bupivacaine HCl 0.5% Injectable Solution
PROCEDURE: primary total knee replacement

Sponsor

Rothman Institute Orthopaedics